Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Membranoproliferative Glomerulonephritis: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Membranoproliferative Glomerulonephritis: 2 US clinical trials tracked, none currently recruiting.
Membranoproliferative Glomerulonephritis is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Apellis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition membranoproliferative-glomerulonephritis
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Membranoproliferative Glomerulonephritis has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Membranoproliferative Glomerulonephritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Membranoproliferative Glomerulonephritis is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Apellis Pharmaceuticals
NCT05809531
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Apellis Pharmaceuticals
NCT04572854
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Membranoproliferative Glomerulonephritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Membranoproliferative Glomerulonephritis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Membranoproliferative Glomerulonephritis page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Membranoproliferative Glomerulonephritis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Apellis Pharmaceuticals sponsors the most Membranoproliferative Glomerulonephritis trials on record, review their full trial history before evaluating a specific study. See Apellis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Membranoproliferative Glomerulonephritis condition card totals 2 registered trials; most-linked intervention Pegcetacoplan; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.